Summary of reporting patterns of disclosed funding source and author-industry FCOI from included RCTs
| Number of meta-analyses reporting funding sources of included RCTs | Number of meta-analyses reporting author financial ties of included RCTs | Number of meta-analyses reporting author–industry employment of included RCTs | |||||||
| Full | Partial | Full or partial | Full | Partial | Full or partial | Full | Partial | Full or partial | |
| Recently published meta-analyses: | |||||||||
| Cochrane (n=107), N (%) | 70 (65) | 20 (19) | 90 (84) | 24 (22) | 23 (21) | 47 (44) | 1 (1) | 17 (16) | 18 (17) |
| Non-Cochrane (n=143), N (%) | 14 (10) | 7 (5) | 21 (15) | 1 (1) | 1 (1) | 2 (1) | 0 | 1 (1) | 1 (1) |
| Difference in reporting between Cochrane and non-Cochrane meta-analyses, % (95% CI) | 56 (44 to 65) | 14 (6 to 23) | 69 (59 to 77) | 22 (14 to 31) | 21 (13 to 30) | 43 (33 to 52) | 1 (−2 to 5) | 15 (9 to 23) | 16 (9 to 24) |
| 2010: | |||||||||
| All Cochrane systematic reviews (n=151), N (%)* | 30 (20) | 16 (11) | 46 (30) | 2 (1) | 9 (6) | 11 (7) | 0 | 10 (7) | 10 (7) |
| Difference in reporting between recently published Cochrane meta-analyses versus Cochrane systematic reviews published in 2010, % (95% CI) | 46 (34 to 56) | 8 (−1 to 18) | 54 (42 to 63) | 21 (13 to 30) | 16 (7 to 25) | 37 (26 to 47) | 1 (−2 to 5) | 9 (2 to 18) | 10 (2 to 19) |
| 2010: | |||||||||
| Cochrane meta-analyses (n=119), N (%) | 21 (19) | 15 (13) | 36 (30) | 0 (0) | 7 (6) | 7 (6) | 0 (0) | 7 (6) | 7 (6) |
| Difference in reporting between recently published Cochrane meta-analyses versus Cochrane meta-analyses published in 2010, % (95% CI) | 48 (36 to 58) | 6 (−3 to 16) | 54 (42 to 63) | 22 (15 to 31) | 16 (7 to 25) | 38 (27 to 48) | 1 (−2 to 5) | 10 (2 to 19) | 11 (3 to 20) |
*Results from Roseman et al.12
FCOI, financial conflicts of interest; RCT, randomised controlled trial.